Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Hormones – e.g. – prolactin – thymosin – growth factors – etc.
Reexamination Certificate
2003-12-10
2008-12-09
Allen, Marianne P. (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Hormones, e.g., prolactin, thymosin, growth factors, etc.
C530S350000, C435S069100, C435S320100, C435S325000, C536S023400, C536S024100
Reexamination Certificate
active
07462700
ABSTRACT:
The present invention provides isolated nucleic acid molecules that encode a substantial part of canine RANKL polypeptide, including the extracellular domains of that polypeptide, the polypeptide and fragments thereof. Vectors and host cells encoding and expressing canine RANKL polypeptide are provided, as well as antibodies that bind to RANKL and that inhibit RANKL activity. Also provided are methods of treating an animal to inhibit or treat the loss of bone minerals.
REFERENCES:
patent: 5843678 (1998-12-01), Boyle
patent: 6017729 (2000-01-01), Anderson et al.
patent: 6242213 (2001-06-01), Anderson
patent: 6242586 (2001-06-01), Gorman et al.
patent: 6316408 (2001-11-01), Boyle
patent: 6419929 (2002-07-01), Anderson
patent: 6525180 (2003-02-01), Gorman et al.
patent: 6645500 (2003-11-01), Halkier et al.
patent: 6838262 (2005-01-01), Anderson et al.
patent: 7192718 (2007-03-01), Yamaguchi et al.
patent: 2002/0081720 (2002-06-01), Dougall et al.
patent: 2002/0086826 (2002-07-01), Anderson et al.
patent: 2002/0086827 (2002-07-01), Anderson
patent: 2002/0169117 (2002-11-01), Maraskovsky
patent: 2003/0175840 (2003-09-01), Anderson et al.
patent: 2003/0176647 (2003-09-01), Yamaguchi et al.
patent: 2003/0198640 (2003-10-01), Yu et al.
patent: 2003/0208045 (2003-11-01), Yamaguchi et al.
patent: 2005/0003391 (2005-01-01), Anderson
patent: 2005/0003457 (2005-01-01), Yamaguchi et al.
patent: 2005/0147611 (2005-07-01), Boyle et al.
patent: 2005/0208580 (2005-09-01), Yamaguchi et al.
patent: 2007/0009520 (2007-01-01), Yamaguchi et al.
patent: WO 96/14328 (1996-05-01), None
patent: WO 97/23614 (1997-07-01), None
patent: WO 98/25958 (1998-06-01), None
patent: WO 98/28424 (1998-07-01), None
patent: WO 98/28426 (1998-07-01), None
patent: WO 98/46751 (1998-10-01), None
patent: WO 00/08139 (2000-02-01), None
patent: WO 00/15807 (2000-03-01), None
patent: WO 01/03719 (2001-01-01), None
patent: WO 01/23549 (2001-04-01), None
patent: WO 02/04643 (2002-01-01), None
Anderson et al., “A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function”Nature, 390(6656):175-179 (1997).
Bax et al., “Stimulation of osteoclastic bone resorption by hydrogen peroxide”,Biochemical and Biophysical Research Communications, 183(3):1153-1158 (1992).
Bertolini et al., “Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors”,Nature, 319:516-518 (1986).
Bolin et al., “HNMP-1: A Novel Hematopoietic and Neural Membrane Protein Differentially Regulated in Neural Development and Injury”,The Journal of Neuroscience, 17(14):5493-5502 (1997).
Chambers, T. J., “Regulation of the differentiation and function of osteoclasts”,Journal of Pathology, 192(1):4-13 (2000).
Collin et al., “Constitutive expression of osteoclast-stimulating activity by normal clonal osteoblast-like cells: effects of parathyroid hormone and 1,25- dihydroxyvitamin D3”Endocrinology, 131(3):1181-1187 (1992).
Cunningham et al., “Receptor and Antibody Epitopes in Human Growth Hormone Identified by Homolog-Scanning Mutagenesis”Science, 243:1330-1336 (1989).
Hall et al., “The Role of Reactive Oxygen Intermediates in Osteoclastic Bone Resorption”,Biochemical and Biophysical Research Communications, 207(1):280-287 (1995).
Hughes et al., “Genetic linkage of familial expansile osteolysis to chromosome 18q”,Hum. Mol. Genet., 3(2):359-361 (1994).
Jimi et al., “Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact”,Endocrinology, 137(5):2187-2190 (1996).
Kearns et al., “RANKL and OPG Regulation of Bone Remodeling in Health and Disease”,Endocr. Rev., pp. I-84; Rapid Electronic Publication first published on Dec. 5, 2007 as doi:10.1210/cr.2007-0014.
Khosla, S., “Minireview: The OPG/RANKL/RANK System”,Endocrinology, 142(12): 50505-5055 (2001).
Kukita and Kukita, “Invited Review. Osteoclast differentiation antigen”,Histology and Histopathology, 11:821-830 (1996).
Lacey et al., “Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation”,Cell, 93(2)165-176 (1998).
Libermann and Baltimore, “Activation of interleukin-6 gene expression through the NF-kappa B transcription factor”,Mol. Cell. Biol., 10 (5):2327-2334 (1990).
Marie et al., “In vitro production of cytokines by bone surface-derived osteoblastic cells in normal and osteoporotic postmenopausal women: relationship with cell proliferation”,J Clin Endocrinol Metab, 77(3):824-830 (1993).
Mc Hugh et al., “Receptor activator of NF-κB ligand arrests bone growth and promotes cortical bone resorption in growing rats”,J Appl Physiol95: 672-676 (2003).
Mee et al., “Dogs, Distemper and Paget's Disease”,BioEssays, 15(12):783-789 (1993).
O'Dowd et al., “Site-directed mutagenesis of the cytoplasmic domains of the human beta 2-adrenergic receptor. Localization of regions involved in G protein- receptor coupling”,J. Biol. Chem., 263(31):15985-15992 (1988).
Pacifici et al., “Spontaneous Release of Interleukin 1 from Human Blood Monocytes Reflects Bone Formation in Idiopathic Osteoporosis”,PNAS, 84(13): 4616-4620 (1987).
Pacifici et al., “Effect of Surgical Menopause and Estrogen Replacement on Cytokine Release from Human Blood Mononuclear Cells”,PNAS, 88(12): 5134-5138 (1991).
Schoppet et al., “RANK Ligand and Osteoprotegerin: Paracrine Regulators of Bone Metabolism and Vascular Function”,Arterioscler Thromb Vasc Biol., 22:549-553 (2002); published online before print Jan. 31, 2002, doi:10.1161/01.ATV.0000012303.37971.DA.
Simonet et al., “Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density”Cell, 89(2):309-319 (1997).
Suda et al., “Modulations of Osteoclast Differentiation”,Endocrine Reviews, 13(1):66-80 (1992).
Suda et al., “Modulations of Osteoclast Differentiation: Update 1995”,Endocrine Reviews, 4(1):266-270 (1995).
Suda et al., “Modulations of Osteoclast Differentiation by Local Factors”,Bone, 17(2, Supp.):87S-91S (1995).
Takahashi et al., “A New Member of Tumor Necrosis Factor Ligand Family, ODF/OPGL/TRANCE/RANKL, Regulates Osteoclast Differentiation and Function”,Biochemical and Biophysical Research Communications, 256(3):449-455 (1999).
Tashjian et al., “Tumor Necrosis Factor-α (Cachectin) Stimulates Bone Resorption in Mouse Calvaria via a Prostaglandin-Mediated Mechanism”,Endocrinology, 120(5):2029-2036 (1987).
Thomson et al., “Osteoblasts mediate interleukin 1 stimulation of bone resorption by rat osteoclasts”,J. Exp. Med., 164(1):104-112 (1986).
Thomson et al., “Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption”,J. Immunol., 138(3):775-779 (1987).
Tsuda et al., “Isolation of a Novel Cytokine from Human Fibroblasts That Specifically Inhibits Osteoclastogenesis”,Biochemical and Biophysical Research Communications, 234(1):137-142 (1997).
Wong et al., “TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells”,J. Biol. Chem., 272(40):25190-25194 (1997).
Yasuda et al., “Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in Vitro”,Endocrinology, 139(3):1329-1337 (1998).
Yasuda et al., “Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL”,Proc. Natl. Acad. Sci. USA; 95(7):3597-3602 (1998).
Mattson Jeanine D.
McClanahan Terrill
Allen Marianne P.
DeBerry Regina M
Schering-Plough Animal Health Corporation
LandOfFree
Canine RANKL and methods for preparing and using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Canine RANKL and methods for preparing and using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Canine RANKL and methods for preparing and using the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4036361